Children Over 40kg Should Not Receive Augmentin Liquid Suspension
For children weighing more than 40 kg, Augmentin oral suspension should not be prescribed—these patients should receive adult tablet formulations instead. 1
Why Liquid Formulations Are Inappropriate
The FDA-approved Augmentin ES-600 oral suspension explicitly states: "Pediatric patients weighing 40 kg and more: Experience with AUGMENTIN ES-600 Powder for Oral Suspension in this group is not available" and "adults who have difficulty swallowing should not be given AUGMENTIN ES-600 Powder for Oral Suspension in place of the 500-mg or 875-mg tablet of AUGMENTIN." 1
This weight threshold exists because:
- Volume limitations: Children ≥40 kg would require excessively large volumes of suspension to achieve therapeutic dosing
- Lack of clinical data: No safety or efficacy studies exist for suspension use in this weight category
- Formulation design: The suspension was specifically developed and tested for smaller pediatric patients
What to Prescribe Instead
Use adult tablet formulations:
- Standard dosing: Augmentin 500 mg/125 mg tablets three times daily OR 875 mg/125 mg tablets twice daily 1
- For resistant pathogens: Augmentin XR 2000 mg/125 mg twice daily (pharmacokinetically enhanced formulation) 2
The tablet formulations provide appropriate dosing for patients in this weight range and have established safety profiles.
Clinical Context from Guidelines
While the provided pneumonia guidelines 3, 4, 3, 4, 3, 4, 3 discuss amoxicillin/clavulanate dosing for various pathogens, they specify weight-based dosing (45-90 mg/kg/day of the amoxicillin component) without addressing the practical limitation that suspension formulations cannot accommodate children ≥40 kg. The guidelines recommend amoxicillin/clavulanate for β-lactamase-producing Haemophilus influenzae at 45 mg/kg/day in 3 doses or 90 mg/kg/day in 2 doses, but these recommendations apply to children who can appropriately use suspension formulations.
Common Prescribing Error to Avoid
Do not attempt to prescribe multiple bottles of suspension or excessive volumes per dose to achieve therapeutic levels in children ≥40 kg. This approach:
- Lacks FDA approval
- Has no supporting clinical data
- Creates adherence problems
- Increases cost unnecessarily
- May lead to dosing errors
The transition to tablets at 40 kg is a hard cutoff based on formulation design and regulatory approval, not a clinical judgment call.